NCT06495723View on ClinicalTrials.gov

Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Peripheral T Cells Lymphoma (PTCL)
Interventions
DRUG

LIS1

The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.

Trial Locations (8)

14033

RECRUITING

CHU de Caen, Caen

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

33604

RECRUITING

CHU de Bordeaux - GH Sud - Hôpital Haut-Lévêque, Pessac

40138

RECRUITING

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna

63003

RECRUITING

CHU de Clermont-Ferrand, Clermont-Ferrand

69310

RECRUITING

CHU de Lyon - Hôpital Lyon Sud, Pierre-Bénite

80131

RECRUITING

"SC Ematologia Istituto Nazionale dei TumoriIRCCS Fondazione G. Pascale", Napoli

94000

RECRUITING

CHU Henri-Mondor, Créteil

All Listed Sponsors
lead

Xenothera SAS

INDUSTRY